[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"First Affiliated Hospital of Xinjiang Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":150},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,74,104,126],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100561171","phase-4-effect-of-small-interfering-rna-inclisiran-on-carotid-plaques-as-assessed-by-carotid-ultrasound-100561171",false,"NCT06586684","Effect of Small Interfering RNA Inclisiran on Carotid Plaques As Assessed by Carotid Ultrasound","The Effect of Small Interfering RNA Inclisiran on Carotid Plaques in Patients with Atherosclerosis: a Real-world Study Using Carotid Ultrasound.","Inclusion Criteria:\n\n* Patients with carotid plaques as indicated by ultrasound\n* Men and women aged 18-75 years;\n* LDL-C \\>3.4 mmol\u002FL without regular statin therapy or LDL-C \\>1.8 mmol\u002FL after 4 weeks of statin lipid-lowering therapy.\n\nExclusion Criteria:\n\n* \\- Known allergies or contraindications to PCSK9 inhibitors and\u002For statin therapy;\n* Prior use of PCSK9 inhibitors;\n* Prior history of hemorrhagic stroke;\n* Prior coronary artery bypass grafting or coronary intervention;\n* Inability to perform OCT imaging or unclear imaging;\n* Severe renal insufficiency (creatinine clearance \\< 30 mL\u002Fmin);\n* Severe hepatic dysfunction;\n* Baseline triglycerides \\> 5.6 mmol\u002FL;\n* Pregnant or lactating women;\n* Life expectancy not exceeding 1 year;\n* In the judgment of the investigator, unsuitable for this study for any reason.","ALL","18 Years","75 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Current understanding suggests that the majority of cardiovascular events are driven by vulnerable plaques. Nonetheless, the impact of PCSK9 inhibitors on the stability of carotid plaques remains insufficiently elucidated, with a notable scarcity of relevant clinical studies. This investigation seeks to address this gap through a real-world study conducted among patients with arterial sclerosis in Asia. The primary aim is to evaluate the effects of small interfering RNA (inclisiran) on carotid plaque characteristics as assessed by ultrasound, thereby contributing valuable data to inform clinical practice.",[27,28,29],"Carotid Plaque","Hyperlipidemia","Echocardiography",[31,32,29,33],"inclisiran","carotid plaque","hyperlipidmia","NOT_YET_RECRUITING","2024-09-04",{"date":37,"type":38},"2024-09-19","ACTUAL",{"date":40,"type":21},"2024-09-20",{"date":42,"type":21},"2026-09-30",{"name":44,"class":45},"First Affiliated Hospital of Xinjiang Medical University","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100556116","phase-4-effect-of-pcsk9-inhibitors-on-coronary-atherosclerotic-plaques-derived-from-optical-coherence-tomography-100556116","NCT06520904","Effect of PCSK9 Inhibitors on Coronary Atherosclerotic Plaques Derived From Optical Coherence Tomography","Effect of PCSK9 Inhibitors on Coronary Atherosclerotic Plaques Derived From Optical Coherence Tomography in Patients With Premature Coronary Artery Disease: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Men aged 18-55 years and women aged 18-65 years;\n* CAD patients with coronary angiographically confirmed lesions in ≥2 vessels; at least one vessel was critically diseased (50-70% stenosis level);\n* LDL-C \\>3.4 mmol\u002FL without regular statin therapy or LDL-C \\>1.8 mmol\u002FL after 4 weeks of statin lipid-lowering therapy.\n\nExclusion Criteria:\n\n* Known allergies or contraindications to PCSK9 inhibitors and\u002For statin therapy;\n* Prior use of PCSK9 inhibitors;\n* Prior history of hemorrhagic stroke;\n* Prior coronary artery bypass grafting or coronary intervention;\n* Inability to perform OCT imaging or unclear imaging;\n* Severe renal insufficiency (creatinine clearance \\\u003C 30 mL\u002Fmin);\n* Severe hepatic dysfunction;\n* Baseline triglycerides \\> 5.6 mmol\u002FL;\n* Pregnant or lactating women;\n* Life expectancy not exceeding 1 year;\n* In the judgment of the investigator, unsuitable for this study for any reason.","65 Years",{"count":55,"type":21},396,[24],"The presence of coronary atherosclerotic vulnerable plaque significantly impacts the clinical outcomes of patients diagnosed with coronary artery disease (CAD). However, the influence of PCSK9 inhibitors on stabilizing coronary atherosclerotic plaques in individuals with early-onset CAD, evaluated through optical coherence tomography (OCT), remains inadequately understood. Moreover, there is a notable absence of relevant randomized controlled trials investigating this phenomenon. This current study represents a single-center, randomized, controlled, open-label trial conducted among Asian patients with early-onset CAD. Its principal objective was to explore the effects of PCSK9 inhibitors on coronary atherosclerotic plaque morphology as assessed by OCT.",[59,60],"Coronary Artery Disease","Optical Coherence Tomography",[59,62,63,60],"Lipid-lowering Therapy","PCSK9","RECRUITING","2024-08-16",{"date":67,"type":38},"2024-08-19",{"date":69,"type":38},"2024-07-01",{"date":71,"type":21},"2026-12-31",{"name":44,"class":45},1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":103,"locationsCount":4},"100552059","efficacy-of-local-antibiotic-injection-via-a-catheter-for-treating-acute-periprosthetic-infections-after-knee-dair-surgery-100552059","NCT06468163","Efficacy of Local Antibiotic Injection Via a Catheter for Treating Acute Periprosthetic Infections After Knee DAIR Surgery","Efficacy of Local Antibiotic Injection Via a Catheter for Treating Acute Periprosthetic Infections After Knee DAIR Surgery: A Prospective, Randomized Controlled Trial Study","YES","Inclusion Criteria:\n\n1. Age ≥18 years old, gender is not limited;\n2. Meet the diagnostic criteria for DAIR surgery of artificial knee joint;\n3. Receiving knee DAIR surgery;\n4. Voluntary and signed informed consent.\n\nExclusion Criteria:\n\n1. Patients with chronic PJI infection undergoing total knee revision;\n2. Patients with severe knee joint infection who cannot undergo artificial joint replacement;\n3. Progressive renal insufficiency (stage 4 and above) or glomerular filtration rate less than 30ml\u002Fmin;\n4. periprosthesis infection after multiple joint replacement;\n5. Active infection at the site of intravenous or joint injection;\n6. long-term use of anticoagulants or antiplatelet drugs due to other diseases;\n7. Have sepsis or positive blood culture within the last 30 days;\n8. Radiotherapy and chemotherapy are required due to neoplastic diseases;\n9. Receiving systemic glucocorticoid therapy (prednisone \\> 10mg\u002F day or equivalent hormone medication);\n10. severe immunodeficiency diseases (such as stage 3 HIV, sickle cell anemia, splenectomy, etc.);\n11. Have a history of drug abuse;\n12. Treatment of bone marrow or other transplants with immunosuppressive drugs;\n13. Pregnant, parturient and lactating women;\n14. Participating in other clinical trials;\n15. Researchers believe that other reasons are not appropriate for clinical trial participants.","80 Years",{"count":84,"type":21},200,[86],"NA","Prosthetic Joint Infection (PJI) is a severe complication following joint replacement surgery, imposing significant economic and health burdens on patients. For acute PJI, the DAIR (Debridement, Antibiotics, and Implant Retention) procedure is a necessary and effective treatment method, as it effectively clears the infection while preserving the prosthesis, thereby avoiding more complex surgical interventions. However, the practice of using drainage tubes postoperatively is controversial. Some studies suggest that drainage tubes may increase the risk of infection, while other literature indicates no statistically significant difference in infection risk associated with their use.In this context, Professor Li Cao's team at Xinjiang Medical University has improved the traditional DAIR procedure by incorporating long-term local antibiotic injections post-surgery, achieving positive results. Despite this, the specific method of antibiotic injection, particularly whether to use a drug infusion tube, remains under debate. The use of an infusion tube can reduce patient discomfort, shorten the local disinfection process, and theoretically decrease the time the incision is exposed to the external environment, potentially lowering the infection risk. However, the validity of these theoretical assumptions needs further confirmation through high-level scientific research. This study aims to evaluate whether there are differences in joint function recovery, changes in blood infection markers, and the incidence of postoperative complications between using and not using an infusion tube for local antibiotic injection after knee DAIR surgery. To assess the value of the infusion tube in local antibiotic injection post-knee DAIR surgery, a randomized controlled trial (RCT) will be conducted. Eligible patients will be randomly assigned to the infusion tube group (experimental group) or the non-infusion tube group (control group). The study will prospectively collect basic information, joint function scores, blood infection markers, and postoperative complication data from both groups, including patient age, gender, educational background, and postoperative blood test results. Ultimately, the RCT aims to demonstrate the therapeutic efficacy of the infusion tube method.",[89],"Local Antibiotic Injection Catheter Acute Periprosthetic Infections Knee DAIR Randomized Controlled Trial",[91,92,93,94,95,96],"Local Antibiotic Injection","Catheter","Acute Periprosthetic Infections","DAIR Surgery","Prospective","Randomized Controlled Trial","2024-06-15",{"date":99,"type":38},"2024-06-21",{"date":101,"type":21},"2024-08-01",{"date":71,"type":21},{"name":44,"class":45},{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":111,"sex":16,"minAge":17,"maxAge":82,"enrollmentInfo":112,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":122,"startDateStruct":123,"completionDateStruct":124,"leadSponsor":125,"locationsCount":4},"100552026","prospective-cohort-study-of-synovial-biomarkers-in-the-diagnosis-and-prediction-of-periprosthetic-joint-infection-100552026","NCT06467734","Prospective Cohort Study of Synovial Biomarkers in the Diagnosis and Prediction of Periprosthetic Joint Infection","Yes","Inclusion Criteria:\n\n1. Age ≥18 years old, gender is not limited;\n2. The experimental group met the diagnostic criteria of chronic periprosthesis infection after joint replacement according to the 2018 Musculoskeletal Infection Association; The control group was eligible for primary replacement patients who excluded periprosthesis infection.\n3. Voluntary and signed informed consent.\n\nExclusion Criteria:\n\n1. Patients with immune-related arthritis such as rheumatoid and rheumatism were excluded;\n2. Radiotherapy and chemotherapy are required due to neoplastic diseases;\n3. Receiving systemic glucocorticoid therapy (prednisone \\> 10mg\u002F day or equivalent hormone medication);\n4. Severe immunodeficiency diseases (such as stage 3 HIV, sickle cell anemia, splenectomy, etc.);\n5. Have a history of drug abuse;\n6. Use immunosuppressive drugs to treat bone marrow or other transplants;\n7. Pregnant, parturient and lactating women;\n8. Participating in other clinical trials;\n9. Researchers consider other reasons not appropriate for clinical trial participants.",true,{"count":84,"type":21},"OBSERVATIONAL","Prosthetic Joint Infection (PJI) is one of the severe complications following arthroplasty. With the global aging population, the number of patients undergoing primary joint replacement surgeries is increasing, leading to a rise in PJI cases. Although the incidence of PJI is generally low, the impact on patients can be catastrophic. Once an infection occurs, it is further complicated by the rising global antibiotic resistance, imposing a significant economic burden on patients. Therefore, improving the diagnostic rate of PJI is crucial. Currently, various infection markers are used in the diagnosis of PJI. However, there is still a lack of highly sensitive and specific markers to effectively diagnose PJI, necessitating the exploration of new infection markers. This study aims to investigate novel infection markers for the diagnosis of PJI, providing evidence for its diagnosis and subsequent treatment. In this research, we will prospectively collect data from patients undergoing primary joint replacement and those developing PJI from June 2024 to December 2026. These patients will be categorized into non-infection and infection groups. By collecting and analyzing general patient data, surgery-related information, and infection-related indicators from preoperative joint fluid and blood samples, we aim to further evaluate the predictive value of these infection markers for PJI.",[108],[117,118,119,120,121],"Prospective cohort study","synovial biomarkers","diagnosis","prediction","periprosthetic joint infection",{"date":99,"type":38},{"date":101,"type":21},{"date":71,"type":21},{"name":44,"class":45},{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":109,"eligibilityCriteria":132,"healthyVolunteers":111,"sex":16,"minAge":17,"maxAge":82,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":136,"conditions":137,"keywords":141,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":148,"leadSponsor":149,"locationsCount":4},"100552025","clinical-efficacy-of-self-adhesive-silicone-gel-waterproof-dressings-versus-conventional-dressings-in-the-healing-of-incisions-after-total-joint-arthroplasty-100552025","NCT06467721","Clinical Efficacy of Self-adhesive Silicone Gel Waterproof Dressings Versus Conventional Dressings in the Healing of Incisions After Total Joint Arthroplasty","Clinical Efficacy of Self-adhesive Silicone Gel Waterproof Dressings Versus Conventional Dressings in the Healing of Incisions After Total Joint Arthroplasty: a Prospective, Randomized Controlled Trial Study","Inclusion Criteria:\n\n1. Age ≥18 years old, gender is not limited;\n2. Meet the diagnostic criteria for artificial joint replacement;\n3. Initial joint replacement surgery;\n4. Voluntary and signed informed consent.\n\nExclusion Criteria:\n\n1. Allergic to self-adhesive silicone rubber waterproof dressing;\n2. Patients with severe knee joint infection who cannot undergo artificial joint replacement;\n3. Progressive renal insufficiency (stage 4 and above) or glomerular filtration rate less than 30ml\u002Fmin;\n4. periprosthesis infection after multiple joint replacement;\n5. Active infection at the site of intravenous or joint injection;\n6. long-term use of anticoagulants or antiplatelet drugs due to other diseases;\n7. Have sepsis or positive blood culture within the last 30 days;\n8. Radiotherapy and chemotherapy are required due to neoplastic diseases;\n9. Receiving systemic glucocorticoid therapy (prednisone \\> 10mg\u002F day or equivalent hormone medication);\n10. severe immunodeficiency diseases (such as stage 3 HIV, sickle cell anemia, splenectomy, etc.);\n11. Have a history of drug abuse;\n12. Treatment of bone marrow or other transplants with immunosuppressive drugs;\n13. Pregnant, parturient and lactating women;\n14. Participating in other clinical trials;\n15. Researchers believe that other reasons are not appropriate for clinical trial participants.",{"count":134,"type":21},600,[86],"The efficacy of using self-adhesive silicone gel waterproof dressings versus conventional gauze dressings for recovery after total joint arthroplasty (TJA) remains unclear. In our study, we conducted a prospective, randomized controlled trial to compare these two types of dressings. Patients were divided into two groups following TJA, and we collected primary outcome measures such as skin infection rate and re-operation rate. Additionally, we gathered blood inflammatory indicators, including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), to evaluate the effectiveness of the two treatments. Finally, we perform one year follow up including REEDA score, MSS score to evaluate the recovery of the skin.",[138,139,140],"Self-adhesive Silicone Gel Waterproof Dressing","Gauze Dressing","Total Joint Arthroplasty",[142,143,144,145],"self-adhesive silicone gel waterproof dressing","gauze dressing","total joint arthroplasty","RCT",{"date":99,"type":38},{"date":101,"type":21},{"date":71,"type":21},{"name":44,"class":45},""]